Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: RETRACTED ARTICLE: A positive feedback loop consisting of C12orf59/NF-κB/CDH11 promotes gastric cancer invasion and metastasis

Fig. 1

C12orf59 is elevated in GC tissues and correlated with poor survival outcome in GC patients. a Left panel: Western blotting (upper) and qPCR (lower) analysis of C12orf59 protein expression in 8 pairs of matched GC tissues (T) and adjacent noncancerous tissues (ANT). Right panel: Western blotting (upper) and qPCR (lower) assay of C12orf59 expression in GSE1 and five GC cell lines; GAPDH was used as a loading control. b Representative image of negative C12orf59 IHC staining (Scoring intensity = 0) in normal gastric tissues, and representative images of negative Scoring intensity = 0), weak (Scoring intensity = 1), moderate (Scoring intensity = 2) and strong (Scoring intensity = 3) C12orf59 IHC staining in GC tissues is shown. c X-tile plots of the prognostic marker of C12orf59 in the two GC cohorts. X-tile analysis was carried out on patient data from the training cohort, equally subdivided into training and validation subsets. X-tile plots of training sets are displayed in the left panels, with matched validation sets in the smaller inset. The plot showed the χ2 log-rank values created when the cohort was divided into two populations. The cut point was demonstrated on a histogram of the entire cohort (middle panels) and a Kaplan–Meier plot (right panels). P values were defined by using the cut point derived from a training subset to parse a separate validation subset. (Upper panel) C12orf59 expression was divided at the optimal cut point, as defined by the most significant on the plot (with positive staining of C12orf59; P < 0.001). (Lowe panel) The optimal cut point for C12orf59 expression determined by X-tile plot of the testing cohort was applied to the validation cohort and reached high statistical significance (P < 0.001). The IHC score was determined by multiplying the intensity score with the percentage of positive cells in tumor tissues. d. IHC analysis of C12orf59 expression in primary and metastatic GC tissues. e. ROC curve analysis for different clinicopathological features and C12orf59 expression was performed to evaluate the survival status. Left panel: age (AUC = 0.575; P = 0.104), gender (AUC = 0.501; P = 0.975), grade (AUC = 0.393; P = 0.540), tumor size(AUC = 0.572; P = 0.119), T status (AUC = 0.631; P = 0.005), N status (AUC = 0.651; P = 0.001), clinical stage (AUC = 0.689; P < 0.001) and C12orf59 expression (AUC = 0.840; P < 0.001) implied statistical associations with survival in the training cohort; Right panel: age (AUC = 0.543; P = 0.443), gender (AUC = 0.538; P = 0.500), grade (AUC = 0.564; P = 0.257), tumor size(AUC = 0.604; P = 0.066), T status (AUC = 0.595; P = 0.092), N status (AUC = 0.665; P = 0.004), clinical stage (AUC = 0.693; P = 0.001) and C12orf59 expression (AUC = 0.663; P = 0.004) were used to test the survival status in validation cohort

Back to article page